[Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results -- Q3 2009 revenue increased 106.3% to $15.6 million; Q3 Gross Margins of 77.0% -- Q3 2009 net income increased 459.2% to $3.1 million with EPS of $0.13 -- Revenue for the first nine months increased 52.5 % to $36.2 million; net income increased 112.9% to $8.8 million with EPS]
[Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results -- Q3 2009 revenue increased 106.3% to $15.6 million; Q3 Gross Margins of 77.0% -- Q3 2009 net income increased 459.2% to $3.1 million with EPS of $0.13 -- Revenue for the first nine months increased 52.5 % to $36.2 million; net income increased 112.9% to $8.8 million with EPS]
[1 Name of Reporting Person Andrew Barron Worden I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds PF Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Number of 7 Sole Voting Power Shares Owned]
[1 Name of Reporting Person Andrew Barron Worden I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds PF Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Number of 7 Sole Voting Power Shares Owned]
[Biostar Pharmaceuticals, Announces Record Third Quarter 2009 Financial Results -- Q3 2009 revenuereased 106.3% to $15.6 million; Q3 Gross Margins of 77.0% -- Q3 2009 netomereased 459.2% to $3.1 million with EPS of $0.13 -- Revenue for the first nine monthsreased 52.5 % to $36.2 million; netomereased 112.9% to $8.8 million with EPS of $0.37]
[Biostar Pharmaceuticals, Announces Record Third Quarter 2009 Financial Results -- Q3 2009 revenuereased 106.3% to $15.6 million; Q3 Gross Margins of 77.0% -- Q3 2009 netomereased 459.2% to $3.1 million with EPS of $0.13 -- Revenue for the first nine monthsreased 52.5 % to $36.2 million; netomereased 112.9% to $8.8 million with EPS of $0.37]
[SCHEDULE 13D Biostar Pharmaceuticals, (Name of Issuer)mmon Stock (Title of Class of Securities) 090678103 (CUSIP Number) Rebecca Baum 730 FIFTH AVENUE, 25TH FLOOR NEW YORK, NY 10019 212-359-0204 (Name,dress and Telephone Number of Person Authorized to Receive Notices andmmunications) November 02, 2009 (Date of Event which Requires Filing of this Statement) If the filing person]
[SCHEDULE 13D Biostar Pharmaceuticals, (Name of Issuer)mmon Stock (Title of Class of Securities) 090678103 (CUSIP Number) Rebecca Baum 730 FIFTH AVENUE, 25TH FLOOR NEW YORK, NY 10019 212-359-0204 (Name,dress and Telephone Number of Person Authorized to Receive Notices andmmunications) November 02, 2009 (Date of Event which Requires Filing of this Statement) If the filing person]
[FORM 10-Q x September 30, 2009 For the quarterly period ended o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ______________ to _____________ 333-147363 BIOSTAR PHARMACEUTICALS, INC. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Road, Xianyang, Shaanxi Province, The People’s Republic] [I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]
[FORM 10-Q x September 30, 2009 For the quarterly period ended o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ______________ to _____________ 333-147363 BIOSTAR PHARMACEUTICALS, INC. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Road, Xianyang, Shaanxi Province, The People’s Republic] [I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]
